There is no dispute with what you say. However Big Pharma as purchaser is free to pursue autism with NNZ-2591 should it decide. 1% of the US populace has autism. That is a market of 3.33 million people. Assume 30% uptake over time at $10k a year and revenues are at $10 billion per annum. Shazam!
There is no dispute with what you say. However Big Pharma as...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.04 |
Change
0.100(0.63%) |
Mkt cap ! $2.052B | |||
| Open | High | Low | Value | Volume |
| $16.25 | $16.32 | $15.84 | $2.415M | 150.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 650 | $16.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.05 | 544 | 20 |
View Market Depth
| Last trade - 11.58am 14/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |